Medigus: Metagramm to Develop Bubbl, its Most Advanced AI-Powered Writing and Grammar Tool
November 13 2023 - 7:45AM
Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in
advanced medical solutions, innovative internet technologies, and
electric vehicle and charging solutions, announced today that its
subsidiary (19.99% owned), Metagramm Software Ltd. (“Metagramm”),
is developing Bubbl, a state-of-the-art writing tool utilizing
Machine Learning, Natural Language Processing (NLP), Artificial
Intelligence (AI) and Deep Learning technologies.
According to Verified Market Research, the
Global Writing Enhancement Software market will reach $887.9
million by 2030 with an impressive 11% CAGR from 2023-2030.
The Company anticipates Bubbl to significantly
impact the market for writing tools, providing users with an
unmatched writing experience.
In an effort to offer an unrivaled user
experience, Bubbl has been crafted with a minimalistic and clean
design, presenting a non-invasive writing tool. It allows users to
operate in different modes, including an interactive re-write
floating window mode, interactive inline mode and grammar-only
mode.
Bubbl represents a revolution in the field of
writing tools, integrating classic semantic analysis, pre-training,
and reinforcement learning of Specialized Language Models (SLMs)
and Large Language Models (LLMs). This advanced technology allows
for innovative document re-writing and sets a new standard in the
domain of writing aids.
A notable feature of Bubbl is "Click Writing", a
unique, user-friendly tool that enables users to enhance and
re-write their text effortlessly. A simple interaction with Bubbl
allows users to access automatically revised text suggestions
instantaneously.
Moreover, Bubbl is designed to cater to a
variety of writing needs with different profiles and features,
including Business, Medical, Academic and Blogging. Each profile
incorporates tailored assistive tools that greatly facilitate the
writing process for each specific profile.
With Metagramm’s new development, Bubbl, Medigus
continues its legacy of pioneering advanced technologies that may
disrupt and redefine their respective fields.
About Medigus
Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is
a technology company focused on innovative growth partnerships,
mainly in advanced medical solutions, digital commerce and electric
vehicle markets. Medigus' affiliations in the medical solutions
arena include ownership in Polyrizon Ltd. The Company’s affiliates
in digital commerce include Gix Internet Ltd., Jeffs' Brands Ltd.
and Eventer Technologies Ltd. In the electric vehicle market,
Charging Robotics Ltd. and Revoltz Ltd., by way of Fuel Doctor
Holdings, Inc. and ParaZero Technologies Ltd. are also part of the
Company’s portfolio of technology solution providers. To learn more
about Medigus’ advanced technologies, please
visit http://www.medigus.com/.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995 and other
Federal securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar
expressions or variations of such words are intended to identify
forward-looking statements. Because such statements deal with
future events and are based on Medigus’ current expectations, they
are subject to various risks and uncertainties, and actual results,
performance or achievements could differ materially from those
described in or implied by the statements in this press release.
For example, Medigus uses forward looking statements when
describing Bubbl’s potential in the global writing enhancement
software market.
The forward-looking statements contained or
implied in this press release are subject to other risks and
uncertainties, including those discussed in any filings with the
SEC. Except as otherwise required by law, Medigus undertakes no
obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. References and links to websites have been provided as a
convenience, and the information contained on such websites is not
incorporated by reference into this press release. Medigus is not
responsible for the contents of third-party websites.
Company Contact:
Tali DinarChief Financial
Officer+972-8-6466-880ir@medigus.com
Investor Relations Contact:
Michal EfratyInvestor Relations,
Israel+972-(0)52-3044404michal@efraty.com
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Apr 2023 to Apr 2024